Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D
- PMID: 23244811
- DOI: 10.1016/j.jval.2012.07.007
Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D
Abstract
Objectives: The 29-item Multiple Sclerosis Impact Scale (MSIS-29) is a psychometrically validated patient-reported outcome measure increasingly used in trials of treatments for multiple sclerosis. However, it is non-preference-based and not amenable for use across policy decision-making contexts. Our objective was to statistically map from the MSIS-29, version 2, to the EuroQol five-dimension (EQ-5D) and the six-dimension health state short form (derived from short form 36 health survey) (SF-6D) to estimate algorithms for use in cost-effectiveness analyses.
Methods: The relationships between MSIS-29, version 2, and EQ-5D and SF-6D scores were estimated by using data from a cohort of people with multiple sclerosis in South West England (n=672). Six ordinary least squares (OLS), Tobit, and censored least adjusted deviation (CLAD) regression analyses were conducted on estimation samples, including the use of subscale and item scores, squared and interaction terms, and demographics. Algorithms from models with the smallest estimation errors (mean absolute error [MAE], root mean square error [RMSE], normalized RMSE) were then assessed by using separate validation samples.
Results: Tobit and CLAD. For the EQ-5D, the OLS models including subscale squared terms, and item scores and demographics performed comparably (MAE 0.147, RMSE 0.202 and MAE 0.147, RMSE 0.203, respectively), and estimated scores well up to 3 years post-baseline. Estimation errors for the SF-6D were smaller (OLS model including squared terms: MAE 0.058, RMSE 0.073; OLS model using item scores and demographics: MAE 0.059, RMSE 0.08), and the errors for poorer health states found with the EQ-5D were less pronounced.
Conclusions: We have provided algorithms for the estimation of health state utility values, both the EQ-5D and SF-6D, from scores on the MSIS-29, version 2. Further research is now needed to determine how these algorithms perform in practical decision-making contexts, when compared with observed EQ-5D and SF-6D values.
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
Similar articles
-
Using the Fatigue Severity Scale to inform healthcare decision-making in multiple sclerosis: mapping to three quality-adjusted life-year measures (EQ-5D-3L, SF-6D, MSIS-8D).Health Qual Life Outcomes. 2019 Aug 5;17(1):136. doi: 10.1186/s12955-019-1205-y. Health Qual Life Outcomes. 2019. PMID: 31382960 Free PMC article.
-
Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.Value Health. 2009 Nov-Dec;12(8):1151-7. doi: 10.1111/j.1524-4733.2009.00569.x. Epub 2009 Jun 25. Value Health. 2009. PMID: 19558372
-
The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.Mult Scler. 2012 Jun;18(6):853-61. doi: 10.1177/1352458511429319. Epub 2011 Nov 22. Mult Scler. 2012. PMID: 22108867
-
A review of the psychometric properties of generic utility measures in multiple sclerosis.Pharmacoeconomics. 2014 Aug;32(8):759-73. doi: 10.1007/s40273-014-0167-5. Pharmacoeconomics. 2014. PMID: 24846760 Review.
-
Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D.Qual Life Res. 2005 Aug;14(6):1523-32. doi: 10.1007/s11136-004-7713-0. Qual Life Res. 2005. PMID: 16110932 Review.
Cited by
-
The External Validity of Mapping MSIS-29 on EQ-5D Among Individuals With Multiple Sclerosis in Sweden.MDM Policy Pract. 2017 Feb 1;2(1):2381468317692806. doi: 10.1177/2381468317692806. eCollection 2017 Jan-Jun. MDM Policy Pract. 2017. PMID: 30288416 Free PMC article.
-
Using the Fatigue Severity Scale to inform healthcare decision-making in multiple sclerosis: mapping to three quality-adjusted life-year measures (EQ-5D-3L, SF-6D, MSIS-8D).Health Qual Life Outcomes. 2019 Aug 5;17(1):136. doi: 10.1186/s12955-019-1205-y. Health Qual Life Outcomes. 2019. PMID: 31382960 Free PMC article.
-
Balance Right in Multiple Sclerosis (BRiMS): a feasibility randomised controlled trial of a falls prevention programme.Pilot Feasibility Stud. 2021 Jan 4;7(1):2. doi: 10.1186/s40814-020-00732-9. Pilot Feasibility Stud. 2021. PMID: 33390184 Free PMC article.
-
Exploring Different Levels of Contact Frequency in Multiple Sclerosis Care.Brain Behav. 2025 Jul;15(7):e70634. doi: 10.1002/brb3.70634. Brain Behav. 2025. PMID: 40619983 Free PMC article.
-
Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.Health Technol Assess. 2020 Jan;24(4):1-182. doi: 10.3310/hta24040. Health Technol Assess. 2020. PMID: 31934845 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical